NO20055894L - Methods and compositions for the treatment of amyloid-related diseases - Google Patents

Methods and compositions for the treatment of amyloid-related diseases

Info

Publication number
NO20055894L
NO20055894L NO20055894A NO20055894A NO20055894L NO 20055894 L NO20055894 L NO 20055894L NO 20055894 A NO20055894 A NO 20055894A NO 20055894 A NO20055894 A NO 20055894A NO 20055894 L NO20055894 L NO 20055894L
Authority
NO
Norway
Prior art keywords
amyloid
treatment
methods
compositions
related diseases
Prior art date
Application number
NO20055894A
Other languages
Norwegian (no)
Other versions
NO335084B1 (en
Inventor
Xianqi Kong
Francine Gervais
Xinfu Wu
David Migneault
Isabelle Valada
Original Assignee
Bhi Ltd Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/871,514 external-priority patent/US7414076B2/en
Priority claimed from US10/871,365 external-priority patent/US7244764B2/en
Application filed by Bhi Ltd Partnership filed Critical Bhi Ltd Partnership
Publication of NO20055894L publication Critical patent/NO20055894L/en
Publication of NO335084B1 publication Critical patent/NO335084B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/69—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a carbon skeleton substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/02—Thiosulfates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Abstract

Metoder, forbindelser, farmasøytiske preparater og sett er beskrevet for behandling eller forhindring av amyloid-relatert sykdom.Methods, compounds, pharmaceutical compositions and kits are described for the treatment or prevention of amyloid-related disease.

NO20055894A 2003-06-23 2005-12-12 Compounds and Preparations and Their Use for the Treatment of Amyloid-Related Diseases NO335084B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48090603P 2003-06-23 2003-06-23
US51204703P 2003-10-17 2003-10-17
US10/871,514 US7414076B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,365 US7244764B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
PCT/IB2004/002375 WO2004113275A2 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases

Publications (2)

Publication Number Publication Date
NO20055894L true NO20055894L (en) 2006-03-21
NO335084B1 NO335084B1 (en) 2014-09-08

Family

ID=33545555

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055894A NO335084B1 (en) 2003-06-23 2005-12-12 Compounds and Preparations and Their Use for the Treatment of Amyloid-Related Diseases

Country Status (12)

Country Link
EP (2) EP1644325A2 (en)
JP (2) JP5146714B2 (en)
KR (1) KR101124935B1 (en)
AU (2) AU2004249529A1 (en)
BR (1) BRPI0411743A (en)
CA (2) CA2529256A1 (en)
EA (1) EA012429B1 (en)
MX (2) MXPA05014166A (en)
NO (1) NO335084B1 (en)
NZ (1) NZ544684A (en)
UA (1) UA96115C2 (en)
WO (2) WO2004113275A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
WO2004113275A2 (en) * 2003-06-23 2004-12-29 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2006059245A2 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
CN101128421A (en) * 2004-12-22 2008-02-20 神经化学（国际）有限公司 Methods and compositions for treating amyloid-related diseases
AU2006321294A1 (en) * 2005-09-30 2007-06-07 Bellus Health (International) Limited Pharmaceutical compositions comprising carboxyalkylsulfonic acids
EP2012789B1 (en) 2006-04-14 2013-09-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (AMD)
US8748656B2 (en) * 2006-10-12 2014-06-10 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2008051017A1 (en) 2006-10-24 2008-05-02 Seoul National University Industry Foundation A cleavage agent selectively acting on soluble assembly of amyloidogenic peptide or protein
EP2132136A2 (en) 2007-03-07 2009-12-16 Massachusetts Institute of Technology Functionalization of nanoscale articles including nanotubes and fullerenes
US8536371B2 (en) * 2007-04-02 2013-09-17 University Of South Alabama Carbon dioxide scrubbing using ionic materials
DK2247558T3 (en) 2008-02-14 2022-02-21 Lilly Co Eli New imaging agents for detecting neurological dysfunction
US8951473B2 (en) 2008-03-04 2015-02-10 Massachusetts Institute Of Technology Devices and methods for determination of species including chemical warfare agents
CN102171185A (en) 2008-08-01 2011-08-31 拜奥西尼斯医药股份有限公司 Methionine analogs and methods of using same
US8420640B2 (en) * 2008-08-29 2013-04-16 Treventis Corporation Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine
WO2010123482A2 (en) 2008-12-12 2010-10-28 Massachusetts Institute Of Technology High charge density structures, including carbon-based nanostructures and applications thereof
US8456073B2 (en) 2009-05-29 2013-06-04 Massachusetts Institute Of Technology Field emission devices including nanotubes or other nanoscale articles
EP2464626A4 (en) 2009-08-10 2015-12-16 Bhi Ltd Partnership Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid
US8187887B2 (en) 2009-10-06 2012-05-29 Massachusetts Institute Of Technology Method and apparatus for determining radiation
KR101173677B1 (en) * 2009-12-11 2012-08-13 한국과학기술연구원 Pharmaceutical composition for preventing or treating diseases associated with beta amyloid accumulation containing EPPS as an active ingredient
US8772537B2 (en) * 2010-07-28 2014-07-08 Sumitomo Chemical Company, Limited Process for producing aminoalkylthiosulfuric acid compound
EP2635525A2 (en) 2010-11-03 2013-09-11 Massachusetts Institute Of Technology Compositions comprising functionalized carbon-based nanostructures and related methods
MX2018001592A (en) * 2015-08-10 2018-08-21 Alzheon Inc Compositions and methods for treating and preventing neurodegenerative disorders.
JP6675167B2 (en) * 2015-08-28 2020-04-01 シスメックス株式会社 Method for releasing and recovering peptide, peptide releasing agent and reagent kit
US9556301B1 (en) 2015-12-02 2017-01-31 King Fahd Universoty of Petroleum and Minerals Cyclopolymer containing residues of methionine and synthesis and uses thereof
EP3424502B1 (en) * 2016-03-04 2022-10-19 Niigata University Aquaporin 4 function promoter and pharmaceutical composition for neurological disorders
RU2657844C1 (en) * 2017-01-09 2018-06-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Method of treatment an experimental amyloid cardiopathy in rats
US11505467B2 (en) 2017-11-06 2022-11-22 Massachusetts Institute Of Technology High functionalization density graphene
PT3762368T (en) 2018-03-08 2022-05-06 Incyte Corp Aminopyrazine diol compounds as pi3k-y inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020025066A1 (en) * 2018-08-03 2020-02-06 The University Of Hong Kong Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli
JP2022059674A (en) * 2020-10-02 2022-04-14 国立大学法人高知大学 Amyloid β aggregation inhibitor, pharmaceutical composition for amyloid β aggregation disease, and its use
EP3992182A1 (en) 2020-10-28 2022-05-04 Cisbio Bioassays Europium(iii) complexes as ph sensors
CN116744912A (en) * 2021-01-11 2023-09-12 苏州华明道康生物医药有限公司 Substituted salicylamide compounds and uses thereof
CN113433325A (en) * 2021-06-07 2021-09-24 西安市第一医院 Application of serum vitronectin in diagnosis and disease classification of AL amyloidosis
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2376911A (en) * 1941-12-24 1945-05-29 Swiss Company Of Soc Of Chemic Derivatives of sulphonated amines and process of preparing same
DE927992C (en) * 1952-07-27 1955-05-23 Hoechst Ag Process for the preparation of salts of 1,2-dimethyl-3-phenyl-4-amino-5-pyrazolone
US3453309A (en) * 1966-10-14 1969-07-01 Parke Davis & Co Phenylalkylaminoethyl thiosulfates
DE2140278A1 (en) * 1970-01-19 1972-03-09 Crompton and Knowles Corp., Worcester, Mass. (V.St.A.) Water-soluble dyes and dye intermediates
US4085134A (en) * 1974-02-15 1978-04-18 Petrolite Corporation Amino-phosphonic-sulfonic acids
JPS60184564A (en) * 1984-03-05 1985-09-20 Mitsui Toatsu Chem Inc Dis-azo dichroic dye for liquid crystal, and liquid crystal composition and display apparatus containing said dye
DD287256A5 (en) * 1989-08-21 1991-02-21 Akademie Der Wissenschaften Der Ddr,De METHOD FOR PRODUCING CHIRAL WATER-SOLUBLE AMMONIUM ALKANSULFONSAEURES AND THEIR SALTS AND SULFOBETAINS
JP3070687B2 (en) * 1990-07-19 2000-07-31 日本臓器製薬株式会社 Heart disease treatment
JP3068841B2 (en) * 1990-08-23 2000-07-24 日本臓器製薬株式会社 Heart disease therapeutic agent containing aminoalkanesulfonic acid derivative as active ingredient
FR2665444B1 (en) * 1990-08-06 1992-11-27 Sanofi Sa AMINO-BENZOFURAN, BENZOTHIOPHENE OR INDOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM.
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
JPH0995444A (en) * 1995-10-02 1997-04-08 Teijin Ltd Agent for inhibiting agglomeration of amyloid protein
WO1997014306A1 (en) * 1995-10-17 1997-04-24 Dovetail Technologies, Inc. Low molecular weight cell, bone marrow and immune stimulants
WO1998052563A1 (en) * 1997-05-21 1998-11-26 Shionogi & Co., Ltd. REMEDIES FOR DEMENTIA OF ALZHEIMER TYPE CONTAINING η-SULTAM DERIVATIVES
MXPA01008606A (en) * 1999-02-26 2003-05-05 Merck & Co Inc Novel sulfonamide compounds and uses thereof.
KR20070094996A (en) * 1999-04-28 2007-09-27 뉴로겜 인터내셔널 리미티드 Compositions and methods for treating amyloidosis
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
EP1237547A2 (en) * 1999-07-09 2002-09-11 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
JP4440446B2 (en) * 1999-10-05 2010-03-24 花王株式会社 Topical skin preparation
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
NZ540564A (en) * 1999-11-29 2007-04-27 Neurochem Int Ltd Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
IL150374A0 (en) * 1999-12-23 2002-12-01 Neurochem Inc Compounds and methods for modulating cerebral amyloid angiopathy
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
NZ541282A (en) * 2002-12-24 2009-02-28 Bellus Health International Ltd Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004113275A2 (en) * 2003-06-23 2004-12-29 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases

Also Published As

Publication number Publication date
CA2529256A1 (en) 2004-12-29
WO2004113277A3 (en) 2005-10-13
WO2004113277A8 (en) 2005-07-14
BRPI0411743A (en) 2006-08-08
UA96115C2 (en) 2011-10-10
WO2004113275A2 (en) 2004-12-29
CA2529257A1 (en) 2004-12-29
EA200600078A1 (en) 2006-08-25
MXPA05014166A (en) 2006-03-13
EA012429B1 (en) 2009-10-30
JP5146714B2 (en) 2013-02-20
KR20060023172A (en) 2006-03-13
NZ544684A (en) 2009-10-30
KR101124935B1 (en) 2012-04-12
WO2004113275A3 (en) 2005-10-27
MXPA05013977A (en) 2006-03-09
EP1644325A2 (en) 2006-04-12
WO2004113277A2 (en) 2004-12-29
NO335084B1 (en) 2014-09-08
EP1658264A2 (en) 2006-05-24
AU2004249527A1 (en) 2004-12-29
AU2004249529A1 (en) 2004-12-29
JP2007516938A (en) 2007-06-28
JP2007516939A (en) 2007-06-28
CA2529257C (en) 2013-04-23

Similar Documents

Publication Publication Date Title
NO20055894L (en) Methods and compositions for the treatment of amyloid-related diseases
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2006085149A3 (en) Methods and compositions for treating amyloid-related diseases
NO20050795L (en) Compounds, compositions and methods for utilizing the same
EA200700225A1 (en) TETRAPTIDE ANALOGUES
ZA200701661B (en) Isoindoline compounds and methods of making and using the same
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
EA201690265A3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED ACYLANILIDES
EA200701930A1 (en) Derivatives of pyrimidine for the treatment of hyperproliferative disorders
NO20061245L (en) Pharmaceutical compositions and processes comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphone
MXPA05009595A (en) 7-amino- isoindolyl compounds amd their pharmaceutical uses.
NO20034056D0 (en) Proliferative diseases
WO2006086562A3 (en) Phenylazetidinone derivatives
MA27880A1 (en) TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
NO20060392L (en) Combination of SRC kinase inhibitors chemotherapeutic agents for the treatment of proliferative diseases
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
DK1641803T3 (en) Thienopyrimidine derivatives as potassium channel inhibitors
NO20076405L (en) Use of 24-nor-UDCA
NO20080037L (en) Combination of Pyrimidylaminobenzamide Compounds and Imatinib for the Treatment or Prevention of Proliferative Diseases
NO20054346L (en) Compositions and methods for the prevention and treatment of endotoxin-related diseases and conditions
NO20054723L (en) Treatment of proliferative diseases with epophilone derivatives and radiation
ATE404550T1 (en) CHEMICAL COMPOUNDS
DK1551850T3 (en) 2 "-oxo-voruscharin and its derivatives

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BHI LIMITED PARTNERSHIP, CA

MM1K Lapsed by not paying the annual fees